One of the largest manufacturers of bronchodilators in Russia has started operations in the Irkutsk Region. The pharmaceutical company Pharmasyntez JSC started the large-scale project for the development and production of bronchodilators at Ginatec LLC.

Key decisions are anticipated in the near future as the company gets ready to release the first batch of drugs for chronic lung diseases, including Chronic Obstructive Pulmonary Disease (COPD).

Olga Danyushkina, the CEO of Ginatec LLC, claims that the company has already developed and registered its first product, Dimpilirin. Future products are about to go on sale and are currently in the active development stage. By the end of the decade, the company plans to manufacture three dozen drug products in total.

Olga Danyushkina, Head of Ginateс, stated:

Our goal is to become one of the leading domestic manufacturers of high-quality, effective, and affordable medications for the treatment of bronchopulmonary diseases. In the medium term, we aim to secure more than 25% of the Russian bronchodilator market.

At its Irkutsk plant, the manufacturer will set up a full-cycle production process that includes the development of finished dosage forms. Over 100 new jobs have already been generated by the project.

The products of Ginatec LLC are intended to lower government spending on the procurement of expensive foreign substitutes, improve population health overall, and greatly increase the availability of up-to-date, high-quality therapy for patients with respiratory pathologies. One of the biggest problems in contemporary medicine is still respiratory disorders. According to the WHO, COPD is among the top six leading causes of death worldwide.

Due to the high prevalence of severe bronchial asthma and COPD, Russia suffers annual economic losses of hundreds of billions of rubles. By offering affordable, high-quality Russian pharmaceuticals that are comparable with overseas medications in terms of both efficacy and safety, Ginatec LLC seeks to reverse this trend.

We currently have a major enterprise in Siberia that produces drugs to treat COPD. We have assumed this role in the region to support the stability of our nation because the number of patients has significantly increased since the COVID-19 pandemic. We have a lot of work ahead of us, and we are ready for it,

Olga Danyushkina said.